19 May 2021 07:00
19 May 2021
Β
Hemogenyx Pharmaceuticals plcΒ
("Hemogenyx Pharmaceuticals" or the "Company")
Β
Director/PDMR Shareholding
Β
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has been notified that Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), has purchased 1,088,120 ordinary shares of Β£0.01 each in the Company ("Ordinary Shares") at an average price of 1.8288 pence per share. Following this transaction, Mr Wright has a total beneficial interest in 2,715,111 Ordinary Shares, representing approximately 0.50 per cent of the Company's issued share capital.
Β
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.
Β
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
Β
Β
1. | Details of PDMR/person closely associated with them ("PCA") | |||||
a) | Name | Andrew Wright | ||||
b) | Position/status | PDMR: Financial Controller and Company Secretary | ||||
c) | Initial notification/amendment | Initial notification | ||||
2. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of Hemogenyx Pharmaceuticals plcIdentification code GB00BYX3WZ24 | ||||
b) | Nature of the transaction | Standalone acquisition of shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price |
| ||||
e) | Date of the transaction | 2021-05-18 | ||||
f) | Place of the transaction | London Stock ExchangeXLON | ||||
Β
Β
Enquiries:
Β
Hemogenyx Pharmaceuticals plc | https://hemogenyx.com |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | headquarters@hemogenyx.com |
Peter Redmond, Director | peter.redmond@hemogenyx.com |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow | |
Β
Follow the stocks